Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis

Incyte (INCY) PT Raised to $109 at BofA Securities

October 28, 2025 10:31 AM EDT

BofA Securities analyst Tazeen Ahmad raised the price target on Incyte (NASDAQ: INCY) to $109.00 (from $104.00) while maintaining a Buy rating.

The analyst comments "Incyte (INCY) reported 3Q revenues for Jakafi of $791mn (+2% q/q, ours: $774mn, cons: $773mn), Opzelura of $188mn (+6% q/q, our:... More